SNT — Syntara Share Price
0.000.00%
Last trade - 00:00- AU$80.53m
- AU$62.62m
- AU$5.43m
- 13
- 19
- 86
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.36 | ||
| Price to Tang. Book | 4.4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.06 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -60.21% | ||
| Return on Equity | -89.17% | ||
| Operating Margin | -139.67% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 12.55 | 22.84 | 14.82 | 5.89 | 5.43 | n/a | n/a | -15.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
Directors
- Malcolm Mccomas NEC (65)
- Gary Phillips CEO (59)
- David McGarvey CFO (64)
- Brett Charlton OTH (64)
- Wolfgang Jarolimek OTH (56)
- Kristen Morgan OTH (48)
- William Delaat NID (69)
- Neil Graham NID
- Kathleen Metters NID (62)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 29th, 1998
- Public Since
- November 10th, 2003
- No. of Shareholders
- 2,387
- No. of Employees
- 107
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,579,112,961
- Address
- 20 Rodborough Rd, FRENCHS FOREST, 2086
- Web
- https://www.pharmaxis.com.au/
- Phone
- +61 294547200
- Contact
- Matthew Wright
- Auditors
- PricewaterhouseCoopers
Upcoming Events for SNT
Similar to SNT
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Syntara share price?
As of Today at 23:32 UTC, shares in Syntara are trading at AU$0.05. This share price information is delayed by 15 minutes.
How has the Syntara share price performed this year?
Shares in Syntara last closed at AU$0.05 and the price had moved by +200% over the past 365 days. In terms of relative price strength the Syntara share price has outperformed the ASX All Ordinaries Index by +195.52% over the past year.
What are the analyst and broker recommendations for Syntara?
The overall consensus recommendation for Syntara is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Syntara dividend yield?
Syntara does not currently pay a dividend.
Does Syntara pay a dividend?
Syntara does not currently pay a dividend.
When does Syntara next pay dividends?
Syntara does not currently pay a dividend.
How do I buy Syntara shares?
To buy shares in Syntara you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Syntara?
As of the previous close price of AU$0.05, shares in Syntara had a market capitalisation of AU$80.53m.
Where are Syntara shares listed?
Here are the trading details for Syntara:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: SNT
What kind of share is Syntara?
Based on an overall assessment of its quality, value and momentum Syntara is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Syntara share price forecast for 2025?
The analyst consensus target price for shares in Syntara is AU$0.18. That is 262.75% above the last closing price of AU$0.05.
Analysts covering Syntara currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.01 for the next financial year.
Find out moreWhat is the trend in the Syntara share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Syntara. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +3.63%.
As of the last closing price of AU$0.05, shares in Syntara were trading -4.9% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Syntara PE Ratio?
The Syntara PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Syntara?
Syntara's management team is headed by:
- Malcolm Mccomas - NEC
- Gary Phillips - CEO
- David McGarvey - CFO
- Brett Charlton - OTH
- Wolfgang Jarolimek - OTH
- Kristen Morgan - OTH
- William Delaat - NID
- Neil Graham - NID
- Kathleen Metters - NID